

Jong Gwang Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6039836/publications.pdf>

Version: 2024-02-01

136
papers

3,924
citations

257101

24
h-index

133063

59
g-index

136
all docs

136
docs citations

136
times ranked

6056
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217. | 2.7 | 9 |
| 2 | Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 78-83. | 0.3 | 1 |
| 3 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618. | 2.7 | 3 |
| 4 | Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy. <i>Chonnam Medical Journal</i> , 2022, 58, 24. | 0.5 | 4 |
| 5 | Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study. , 2022, 39, 141-149. | | 2 |
| 6 | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1. | 1.2 | 0 |
| 7 | Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3639-TPS3639. | 0.8 | 1 |
| 8 | Predictive Value of Circulating miRNAs in Lymph Node Metastasis for Colon Cancer. <i>Genes</i> , 2021, 12, 176. | 1.0 | 8 |
| 9 | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110428. | 1.4 | 6 |
| 10 | Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1279-1286. | 1.0 | 4 |
| 11 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958. | 2.7 | 61 |
| 12 | Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4056-4056. | 0.8 | 1 |
| 13 | Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3598-3598. | 0.8 | 0 |
| 14 | Clinical Impact of Postoperative Vitamin D Deficiency on the Recurrence of Colon Cancer After Curative Surgical Resection. <i>Anticancer Research</i> , 2021, 41, 3683-3688. | 0.5 | 3 |
| 15 | Cisplatin Resistance in Epstein-Barr-Virus-Associated Gastric Carcinoma Acquired through ATM Methylation. <i>Cancers</i> , 2021, 13, 4252. | 1.7 | 1 |
| 16 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153. | 2.7 | 45 |
| 17 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519. | 2.7 | 155 |
| 18 | High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 105-115. | 1.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1455-1465. | 0.7 | 0 |
| 20 | Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62. | 1.3 | 34 |
| 21 | Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>In Vivo</i> , 2020, 34, 1993-1999. | 0.6 | 9 |
| 22 | Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076. | 5.1 | 130 |
| 23 | Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 246-253. | 1.3 | 21 |
| 24 | Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14532-e14532. | 0.8 | 0 |
| 25 | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 185-193. | 0.7 | 1 |
| 26 | Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 4003-4010. | 0.5 | 11 |
| 27 | Quercetin Synergistically Inhibit EBV-Associated Gastric Carcinoma with Ganoderma lucidum Extracts. <i>Molecules</i> , 2019, 24, 3834. | 1.7 | 12 |
| 28 | Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>In Vivo</i> , 2019, 33, 1959-1965. | 0.6 | 8 |
| 29 | Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3127-3136. | 2.0 | 2 |
| 30 | ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Anticancer Research</i> , 2019, 39, 2845-2853. | 0.5 | 6 |
| 31 | Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1286. | 1.8 | 10 |
| 32 | Exon 9 Mutation of <i>PIK3CA</i> Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 2145-2154. | 0.5 | 14 |
| 33 | Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer. <i>In Vivo</i> , 2019, 33, 649-657. | 0.6 | 9 |
| 34 | Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 6973-6979. | 0.5 | 30 |
| 35 | Short-term outcomes after laparoscopic cytoreductive surgery in patients with limited peritoneal metastases from colorectal cancer. <i>Surgery</i> , 2019, 165, 775-781. | 1.0 | 9 |
| 36 | Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 501-508. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239. | 1.3 | 13 |
| 38 | CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1005-1014. | 1.2 | 64 |
| 39 | The Predictive Value of Epstein-Barr Virus-Positivity in Patients Undergoing Gastrectomy Followed by Adjuvant Chemotherapy. <i>Chonnam Medical Journal</i> , 2018, 54, 173. | 0.5 | 6 |
| 40 | Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Medical Oncology</i> , 2018, 35, 145. | 1.2 | 17 |
| 41 | HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 413-423. | 1.4 | 12 |
| 42 | Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 3151-3156. | 0.5 | 7 |
| 43 | Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 187-193. | 1.1 | 5 |
| 44 | AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. <i>Oncology</i> , 2017, 92, 153-160. | 0.9 | 8 |
| 45 | Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760. | 2.9 | 40 |
| 46 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2017, 390, 2461-2471. | 6.3 | 1,749 |
| 47 | DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma. <i>Archives of Pharmacal Research</i> , 2017, 40, 894-905. | 2.7 | 17 |
| 48 | Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. <i>Chonnam Medical Journal</i> , 2017, 53, 140. | 0.5 | 5 |
| 49 | High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>Oncotarget</i> , 2017, 8, 14988-14994. | 0.8 | 34 |
| 50 | Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 208-216. | 0.7 | 13 |
| 51 | Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer. <i>Oncotarget</i> , 2017, 8, 100724-100733. | 0.8 | 55 |
| 52 | Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in Korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance. <i>Journal of Clinical Oncology</i> , 2017, 35, 3605-3605. | 0.8 | 3 |
| 53 | Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 1459-1466. | 0.5 | 22 |
| 54 | Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 293. | 0.8 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Effect of MiR-137 and MiR-496 on Del-1 and triple negative breast cancer progression.. Journal of Clinical Oncology, 2017, 35, e23058-e23058. | 0.8 | 0 |
| 56 | Taxanes in the Treatment of Advanced Gastric Cancer. Molecules, 2016, 21, 651. | 1.7 | 14 |
| 57 | Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 1263-1267. | 1.1 | 4 |
| 58 | Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. Annals of Surgical Oncology, 2016, 23, 894-899. | 0.7 | 9 |
| 59 | Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1775-1780. | 1.2 | 14 |
| 60 | Efficacy of Early Postoperative Intraoperative Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Caseâ€“Control Study from a Single Center. Annals of Surgical Oncology, 2016, 23, 2266-2273. | 0.7 | 7 |
| 61 | Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. Anticancer Research, 2016, 36, 3353-61. | 0.5 | 8 |
| 62 | Current Trends in Studies of Epstein-Barr Virus (EBV) Associated Gastric Carcinoma. Journal of Bacteriology and Virology, 2015, 45, 262. | 0.0 | 1 |
| 63 | Clinical Significance of <i>MET</i> Gene Copy Number in Patients with Curatively Resected Gastric Cancer. Chonnam Medical Journal, 2015, 51, 81. | 0.5 | 2 |
| 64 | Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. Oncology, 2015, 89, 351-359. | 0.9 | 37 |
| 65 | Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 35-41. | 1.2 | 13 |
| 66 | Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemotherapy and Pharmacology, 2015, 76, 29-34. | 1.1 | 0 |
| 67 | Association between GWAS-Identified Genetic Variations and Disease Prognosis for Patients with Colorectal Cancer. PLoS ONE, 2015, 10, e0119649. | 1.1 | 20 |
| 68 | Quercetin-induced apoptosis prevents EBV infection. Oncotarget, 2015, 6, 12603-12624. | 0.8 | 61 |
| 69 | Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. Anticancer Research, 2015, 35, 2775-82. | 0.5 | 20 |
| 70 | Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. Anticancer Research, 2015, 35, 3531-6. | 0.5 | 9 |
| 71 | Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. Blood Research, 2014, 49, 15. | 0.5 | 16 |
| 72 | Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptorâ€“2 gene polymorphisms in patients with gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, e40-5. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Genetic Variations in STK11, PRKAA1, and TSC1 Associated with Prognosis for Patients with Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 634-639. | 0.7 | 20 |
| 74 | AQP1 expression and survival in patients with colon cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14586-e14586. | 0.8 | 3 |
| 75 | Clinical significance of nuclear factor κ B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 785. | 0.7 | 17 |
| 76 | A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. <i>Cancer Research and Treatment</i> , 2014, 46, 19-26. | 1.3 | 9 |
| 77 | Genetic polymorphism in the miR-196a as a prognostic biomarker for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22058-e22058. | 0.8 | 0 |
| 78 | Genetic variant in the microRNA binding site of DOK3 (rs2279398G>A) and susceptibility to colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1537-1537. | 0.8 | 0 |
| 79 | Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22230-e22230. | 0.8 | 0 |
| 80 | Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer. <i>Anticancer Research</i> , 2014, 34, 2943-9. | 0.5 | 24 |
| 81 | PPP1R13L variant associated with prognosis for patients with rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 465-473. | 1.2 | 9 |
| 82 | Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 Expression and Prognosis for Patients with Gastric Cancer. <i>Oncology</i> , 2013, 85, 78-85. | 0.9 | 36 |
| 83 | Genetic variations in miRNA binding site of TPST1 and ZG16B associated with prognosis for patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3553-3553. | 0.8 | 2 |
| 84 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 492-492. | 0.8 | 1 |
| 85 | Molecular targeted therapy for advanced gastric cancer. <i>Korean Journal of Internal Medicine</i> , 2013, 28, 149. | 0.7 | 26 |
| 86 | Phosphorylated AMP-activated protein kinase and MAPK3/1 expression associated with prognosis for patients with gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 36-36. | 0.8 | 2 |
| 87 | AQP5 variant associated with prognosis in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11505-e11505. | 0.8 | 0 |
| 88 | Functional polymorphism in the microRNA-367 binding site as a prognostic factor for colonic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14549-e14549. | 0.8 | 0 |
| 89 | Association of expression of aquaporin 5 (AQP5) with prognosis in hormone-responsive early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11594-e11594. | 0.8 | 0 |
| 90 | Impact of antithymocyte globulin on new HLA groups for unrelated donor allogeneic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18017-e18017. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer. <i>Anticancer Research</i> , 2013, 33, 513-9. | 0.5 | 18 |
| 92 | A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. <i>Anticancer Research</i> , 2013, 33, 3233-9. | 0.5 | 49 |
| 93 | Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1757-1763. | 0.6 | 10 |
| 94 | Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 735-741. | 1.1 | 13 |
| 95 | Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1671-1675. | 1.2 | 9 |
| 96 | Multicenter randomized phase II study of weekly docetaxel alone versus weekly docetaxel plus oxaliplatin as a second-line chemotherapy in patients with advanced gastric cancer: Preliminary response and safety results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14570-e14570. | 0.8 | 2 |
| 97 | PPP1R13L variant as a prognostic factor in patients with rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14074-e14074. | 0.8 | 0 |
| 98 | Prognostic impact of miR-146 polymorphism in patients with resected colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3554-3554. | 0.8 | 0 |
| 99 | The outcomes of allogeneic stem cell transplantation in AML patients with monosomal karyotypes.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6538-6538. | 0.8 | 0 |
| 100 | Clinical significance of nuclear kappa B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18533-e18533. | 0.8 | 0 |
| 101 | Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6536-6536. | 0.8 | 0 |
| 102 | RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 705-713. | 1.2 | 20 |
| 103 | Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 571-577. | 1.1 | 15 |
| 104 | Clinical Significance of Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway in Korean Patients with Colorectal Cancer. <i>Oncology</i> , 2010, 79, 278-282. | 0.9 | 12 |
| 105 | Recent advances in chemotherapy for advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 287. | 0.8 | 5 |
| 106 | No Association of the NFKB1 Insertion/Deletion Promoter Polymorphism with Survival in Patients with Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 497-501. | 0.6 | 8 |
| 107 | Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. <i>International Journal of Hematology</i> , 2009, 90, 383-387. | 0.7 | 54 |
| 108 | TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 355-360. | 1.1 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 953-960. | 1.1 | 22 |
| 110 | Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. <i>Blood</i> , 2009, 114, 5017-5017. | 0.6 | 0 |
| 111 | Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 62-66. | 3.2 | 111 |
| 112 | Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.. <i>Blood</i> , 2008, 112, 2003-2003. | 0.6 | 1 |
| 113 | Clinical Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients.. <i>Blood</i> , 2008, 112, 2205-2205. | 0.6 | 4 |
| 114 | Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 863-869. | 1.1 | 17 |
| 115 | Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 129-134. | 1.1 | 107 |
| 116 | Retrospective Analysis of Post-Remission Modalities in AML Patients with Normal Karyotype.. <i>Blood</i> , 2007, 110, 4258-4258. | 0.6 | 0 |
| 117 | The Mobilization Effects of G-CSF, GM-CSF and Darbepoetin- α for Allogeneic Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4932-4932. | 0.6 | 0 |
| 118 | Early Onset of Acute Graft-Versus-Host Disease Indicating a Worse Prognosis in Terms of Chronic Graft-Versus-Host Disease and Survival Compared to Late Onset.. <i>Blood</i> , 2007, 110, 4979-4979. | 0.6 | 0 |
| 119 | CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 35-39. | 1.1 | 60 |
| 120 | Risk Factors for Predicting CMV Infection in Allogeneic-PBSCT Setting: MNC Dose, Campath Use, and Acute GVHD Grade \geq II.. <i>Blood</i> , 2006, 108, 5298-5298. | 0.6 | 0 |
| 121 | Treatment Outcomes for Imatinib Mesylate and Allogeneic Stem Cell Transplantation in Patients with CML Based on RQ-PCR, and the Efficacy of Dose Escalation of Imatinib Mesylate in Patients with Cytogenetic or Hematologic Resistance.. <i>Blood</i> , 2006, 108, 4762-4762. | 0.6 | 0 |
| 122 | Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. <i>Blood</i> , 2006, 108, 4670-4670. | 0.6 | 0 |
| 123 | Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 885-891. | 0.6 | 58 |
| 124 | Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer. <i>Oncology</i> , 2005, 68, 190-195. | 0.9 | 38 |
| 125 | Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis Type I : Unusual Presentation of Intraabdominal or Intrathoracic Mass. <i>Korean Journal of Internal Medicine</i> , 2005, 20, 100. | 0.7 | 9 |
| 126 | Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5337-5337. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Multidrug Resistance-1 Gene Polymorphism Associated with the Outcomes after Allogeneic HLA-Identical Stem Cell Transplantation.. Blood, 2005, 106, 1757-1757. | 0.6 | 0 |
| 128 | Time to First Acute Exacerbation Can Stratify the Patients According to Their Prognosis during Clinical Course of Chronic GVHD: Evaluation of New End-Point for Chronic GVHD.. Blood, 2005, 106, 5335-5335. | 0.6 | 0 |
| 129 | Rapid Helper T-Cell Recovery at 3 Months Correlates to Successful Transplant Outcomes after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5201-5201. | 0.6 | 0 |
| 130 | Survival Benefit of Asymptomatic Cytomegalovirus Reactivation and Early Lymphocyte Recovery after HLA-Identical Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2005, 106, 5336-5336. | 0.6 | 0 |
| 131 | Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma. Journal of Korean Medical Science, 2004, 19, 820. | 1.1 | 2 |
| 132 | Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. European Journal of Haematology, 2004, 73, 56-61. | 1.1 | 74 |
| 133 | IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2004, 104, 422-422. | 0.6 | 3 |
| 134 | Transplantation with Higher Dose of Natural Killer Cells Associated with Better Outcomes in Terms of Non-Relapse Mortality and Infectious Events after Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Matched Sibling Donors.. Blood, 2004, 104, 733-733. | 0.6 | 2 |
| 135 | Bcl-2 Mediated Apoptosis Interacts with p53-Dependent Pathway in Progression of Peripheral T-Cell Lymphoma.. Blood, 2004, 104, 4548-4548. | 0.6 | 0 |
| 136 | Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. Journal of Clinical Apheresis, 2003, 18, 186-189. | 0.7 | 21 |